Cipla has launched India's first inhalable insulin, Afrezza, after receiving approval from the Central Drugs Standard Control Organisation (CDSCO).

Afrezza, developed by MannKind Corporation in the USA, offers a needle-free, rapid-acting insulin option for diabetes management.

This breakthrough product aims to improve glycemic control for adults with both type 1 and type 2 diabetes who struggle with injectable insulin therapies. The inhalable insulin is delivered through a small inhaler, making it a convenient and non-invasive alternative to traditional injections, particularly for those with needle aversion.

Cipla's introduction of Afrezza in India represents a significant step in expanding access to advanced diabetes care in a country with one of the highest diabetes burdens globally.